Iguratimod

• Description :

  Iguratimod is an antirheumatic agent, acts as an inhibitor of COX-2, with an IC50 of 20 μM (7.7 μg/mL), but shows no effect on COX-1. Iguratimod also inhibits macrophage migration inhibitory factor (MIF) with an IC50 of 6.81 μM.

• CAS Number :

  [123663-49-0]

• Product Name Alternative :

  T614

• UNSPSC :

  12352005

• Hazard Statement :

  H302, H315, H319, H335

• Target :

  COX; Macrophage migration inhibitory factor (MIF)

• Type :

  Reference compound

• Related Pathways :

  Immunology/Inflammation

• Applications :

  COVID-19-immunoregulation

• Field of Research :

  Inflammation/Immunology

• Assay Protocol :

  https://www.medchemexpress.com/iguratimod.html

• Purity :

  99.93

• Solubility :

  DMSO : 33.33 mg/mL (ultrasonic)

• Smiles :

  O=C1C2=CC(OC3=CC=CC=C3)=C(C=C2OC=C1NC([H])=O)NS(=O)(C)=O

• Molecular Formula :

  C17H14N2O6S

• Molecular Weight :

  374.37

• Precautions :

  H302, H315, H319, H335

• References & Citations :

  [1]Tanaka K, et al. T-614, a novel antirheumatic drug, inhibits both the activity and induction of cyclooxygenase-2 (COX-2) in cultured fibroblasts. Jpn J Pharmacol. 1995 Apr;67 (4) :305-14.|[2]Sun Y, et al. Anti-rheumatic drug iguratimod protects against cancer-induced bone pain and bone destruction in a rat model. Oncol Lett. 2017 Jun;13 (6) :4849-4856.|[3]Iguratimod, et al. Identification of Iguratimod as an Inhibitor of Macrophage Migration Inhibitory Factor (MIF) with Steroid-sparing Potential. J Biol Chem. 2016 Dec 16;291 (51) :26502-26514.

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category :

  Reference compound1

• Clinical Information :

  Launched

• Isoform :

  COX-2